[
    [
        {
            "time": "2023-10-01",
            "original_text": "Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Kallyope",
                    "Obesity",
                    "Diabetes",
                    "Drugs"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Novo Nordisk Announces Completion, Headline Results Of Phase 3a Trials PIONEER 4",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Phase 3a Trials",
                    "PIONEER 4",
                    "Completion",
                    "Headline Results"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk Announces Completion, Headline Results Of Phase 3a Trials PIONEER 4",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "LLY vs. NVO: Which Stock Should Value Investors Buy Now?",
            "features": {
                "keywords": [
                    "LLY",
                    "NVO",
                    "Value Investors",
                    "Stock"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "investing"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "LLY vs. NVO: Which Stock Should Value Investors Buy Now?",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]